litlas
Log inCreate account

Robert A. Burger

Active 1994–2025

72
Papers
19,834
Citations
52
h-index
70
i10-index

Citations

Citations per year for Robert A. Burger1993: 1 citations1995: 1 citations1996: 1 citations1998: 4 citations1999: 3 citations2000: 9 citations2001: 27 citations2002: 35 citations2003: 43 citations2004: 65 citations2005: 50 citations2006: 100 citations2007: 156 citations2008: 110 citations2009: 124 citations2010: 140 citations2011: 168 citations2012: 155 citations2013: 119 citations2014: 164 citations2015: 145 citations2016: 167 citations2017: 147 citations2018: 130 citations2019: 605 citations2020: 625 citations2021: 605 citations2022: 446 citations2023: 336 citations2024: 450 citations2025: 227 citations2026: 4 citations1994: no citations, so this year is not shown1997: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,865 citing papers, 27.5% of this breakdownChina: 637 citing papers, 9.4% of this breakdownUnited Kingdom: 425 citing papers, 6.3% of this breakdownItaly: 376 citing papers, 5.6% of this breakdownCanada: 296 citing papers, 4.4% of this breakdownJapan: 280 citing papers, 4.1% of this breakdownGermany: 270 citing papers, 4% of this breakdownFrance: 260 citing papers, 3.8% of this breakdownSpain: 209 citing papers, 3.1% of this breakdownAustralia: 188 citing papers, 2.8% of this breakdownSouth Korea: 156 citing papers, 2.3% of this breakdownIndia: 140 citing papers, 2.1% of this breakdown
0%27.5%Other 24.6%

Institutions

Fields

  • Medicine69.6%
  • Biochemistry, Genetics and Molecular Biology22.5%
  • Immunology and Microbiology3%
  • Materials Science1.6%
  • Neuroscience0.7%
  • Engineering0.6%
  • Other2%

Topics

  • Ovarian cancer diagnosis and treatment14.1%
  • PARP inhibition in cancer therapy5.9%
  • Endometrial and Cervical Cancer Treatments5.9%
  • Intraperitoneal and Appendiceal Malignancies3.9%
  • Cancer Immunotherapy and Biomarkers2.3%
  • Angiogenesis and VEGF in Cancer2%
  • Other65.9%

Coauthors

All papers

Open in search
  1. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

    Authors: Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang - New England Journal of Medicine 2011 cited by 2,384

  2. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

    Authors: Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, Helen E. Michael, Philip J. DiSaia, Larry J. Copeland, William T. Creasman, Frederick B. Stehman, Mark F. Brady, Robert A. Burger, J.T. Thigpen, Michael J. Birrer, Steven Waggoner, David H. Moore, Katherine Y. Look, Wui-Jin Koh, Bradley J. Monk - The Lancet 2017 cited by 679

  3. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

    Authors: Dmitriy Zamarin, Robert A. Burger, Michael W. Sill, Daniel J. Powell, Heather A. Lankes, Michael D. Feldman, Oliver Zivanovic, Camille C. Gunderson, Emily Ko, Cara Mathews, Sudarshan Sharma, Andrea R. Hagemann, Samir N. Khleif, Carol Aghajanian - Journal of Clinical Oncology 2020 cited by 351

  4. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

    Authors: Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Barbara M. Norquist, Elizabeth M. Swisher, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Helen Huang, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Sharon X. Liang, Chenglin Ye, Carlos Bais, Leslie M. Randall, John K. Chan, J. Stuart Ferriss, Robert L. Coleman, Carol Aghajanian, Thomas J. Herzog, Philip J. DiSaia, Larry J. Copeland, Robert S. Mannel, Michael J. Birrer, Bradley J. Monk - Journal of Clinical Oncology 2019 cited by 483

  5. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

    Authors: Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel, Helen Huang, Rebecca N. Baergen, Shashikant Lele, Larry J. Copeland, Joan L. Walker, Robert A. Burger - New England Journal of Medicine 2006 cited by 2,625

  6. Inherited Mutations in Women With Ovarian Carcinoma

    Authors: Barbara M. Norquist, Maria I. Harrell, Mark F. Brady, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Yi Qian, Robert A. Burger, John K. Chan, Susan A. Davidson, Robert S. Mannel, Paul DiSilvestro, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Elizabeth M. Swisher, Michael J. Birrer - JAMA Oncology 2015 cited by 764

  7. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

    Authors: Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Jeffrey M. Fowler, Daniel L. Clarke‐Pearson, Robert A. Burger, Robert S. Mannel, Koen DeGeest, Ellen M. Hartenbach, Rebecca N. Baergen - Journal of Clinical Oncology 2003 cited by 2,055

  8. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

    Authors: Payal D. Shah, Stephanie L. Wethington, Cheyenne Pagan, Nawar Latif, János L. Tanyi, Lainie P. Martin, Mark A. Morgan, Robert A. Burger, Ashley Haggerty, Haley Zarrin, Diego Rodriguez, Susan M. Domchek, Ronny Drapkin, Ie−Ming Shih, Simon A. Smith, Emma Dean, Stéphanie Gaillard, Deborah K. Armstrong, Drew A. Torigian, Wei‐Ting Hwang, Robert Giuntoli, Fiona Simpkins - Gynecologic Oncology 2021 cited by 117

  9. American Society of Clinical Oncology Position Statement on Obesity and Cancer

    Authors: Jennifer A. Ligibel, Catherine M. Alfano, Kerry S. Courneya, Wendy Demark‐Wahnefried, Robert A. Burger, Rowan T. Chlebowski, Carol J. Fabian, Ayca Gucalp, Dawn L. Hershman, Melissa M. Hudson, Lee W. Jones, Madhuri Kakarala, Kirsten K. Ness, Janette K. Merrill, Dana S. Wollins, Clifford A. Hudis - Journal of Clinical Oncology 2014 cited by 524

  10. A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer

    Authors: Kathleen N. Moore, Camille C. Gunderson, Paul Sabbatini, D. Scott McMeekin, Gina Mantia-Smaldone, Robert A. Burger, Mark A. Morgan, Ann M. Kapoun, Rainer K. Brachmann, Robert Stagg, Azeez Farooki, Roisin E. O’Cearbhaill - Gynecologic Oncology 2019 cited by 104

  11. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

    Authors: Benoît You, Christopher Purdy, Larry J. Copeland, Elizabeth M. Swisher, Michael A. Bookman, Gini F. Fleming, Robert L. Coleman, Leslie M. Randall, Krishnansu S. Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, David E. Cohn, Mahvish Muzaffar, David G. Mutch, Andrea E. Wahner Hendrickson, Lainie P. Martin, Olivier Colomban, Robert A. Burger - Journal of Clinical Oncology 2022 cited by 75

  12. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study

    Authors: Barbara M. Norquist, Mark F. Brady, Maria I. Harrell, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Robert A. Burger, Krishnansu S. Tewari, Floor Backes, Robert S. Mannel, Gretchen Glaser, Cheryl L. Bailey, Stephen C. Rubin, John T. Soper, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Michael J. Birrer, Elizabeth M. Swisher - Clinical Cancer Research 2017 cited by 235

  13. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial

    Authors: Robert L. Coleman, Katelyn F. Handley, Robert A. Burger, Graziela Zibetti Dal Molin, Robert Stagg, Anil K. Sood, Kathleen N. Moore - Gynecologic Oncology 2020 cited by 42

  14. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

    Authors: Michael A. Bookman, Mark F. Brady, William P. McGuire, Peter Harper, David S. Alberts, Michael Friedländer, Nicoletta Colombo, Jeffrey M. Fowler, Peter A. Argenta, Koen De Geest, David G. Mutch, Robert A. Burger, Ann Marie Swart, Edward L. Trimble, Chrisann Accario-Winslow, Lawrence M. Roth - Journal of Clinical Oncology 2009 cited by 707

  15. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses

    Authors: Carlos Bais, Barbara M. Mueller, Mark F. Brady, Robert S. Mannel, Robert A. Burger, Wei Wei, Koen M. Marien, Mark Kockx, Amreen Husain, Michael J. Birrer, NRG Oncology/Gynecologic Oncology Group - JNCI Journal of the National Cancer Institute 2017 cited by 108

  16. Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

    Authors: Robert A. Burger, Michael W. Sill, Bradley J. Monk, Benjamin E. Greer, Joel I. Sorosky - Journal of Clinical Oncology 2007 cited by 880

  17. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

    Authors: Ignace Vergote, Giovanni Scambia, David M. O’Malley, Ben Van Calster, Sang‐Yoon Park, Josep M. del Campo, Werner Meier, Aristotelis Bamias, Nicoletta Colombo, Robert M. Wenham, Al Covens, Christian Marth, Mansoor Raza Mirza, Judith R. Kroep, Haijun Ma, Cheryl A. Pickett, Bradley J. Monk, Ignace Vergote, Giovanni Scambia, Sangyoon Park, Yong Sang Song, Yulia Makarova, Joshua Trinidad, Hys Ngan, Aristotelis Bamias, Gerasimos Aravantinos, Joo‐Hyun Nam, Vera Gorbunova, Л. И. Крикунова, Duk‐Soo Bae, Jóse Ángel Arranz Arija, Mansoor Raza Mirza, Claudio Zamagni, Christos N. Papandreou, Francesco Raspagliesi, Alla Lisyanskaya, Ana Oaknin Benzaquen, Germana Tognon, Eugenia Ortega, Antonio Casado Herraez, Joseph Buscema, Andrew Green, Robert A. Burger, Dina Sakaeva, Andres Redondo Sanchez, Sharad Ghamande, Laurel A. King, Edgar Petru, Ulla Peen, Satoshi Takeuchi, Kimio Ushijima, Antonio González-Martı́n, Scott Kamelle, Michael E. Carney, Christian Marth, Frédéric Forget, J. Bentley, Jalid Sehouli, Nicoletta Colombo, Paolo Zola, Hidenori Kato, Natalya Fadeeva, Evgeny Gotovkin, Vladimir Vladimirov, Margarita Romeo Marin, Eva Guerra Alía, Mark S. Shahin, Snehalkumar M Bhoola, Krishnansu S. Tewari, Daniel M. Anderson, Brigitte Honhon, J. Pelgrims, Amit M. Oza, Jesús García-Donás Jiménez, Vincent Hansen, David M. O’Malley, Ivor Benjamin, Vincent Renard, Heidi Van den Bulck, Werner Meier, Claudia Haenle, G. Koumakis, Harushige Yokota, В.М. Попов, William E. Bradley, Robert M. Wenham, Robert H. Reid, Donna McNamara, Richard D. Friedman, Joyce N. Barlin, Nicola M. Spirtos, Julia Chapman, P. Sevelda, Manon Huizing, C. Lamot, Frédéric Goffin, Lionel D. Hondt, Allan Covens, Silvana Spadafora, Beate Rautenberg and 237 more - The Lancet Oncology 2019 cited by 86

  18. Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

    Authors: Stephen A. Cannistra, Ursula A. Matulonis, Richard T. Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey A. Douglas, Robert A. Burger, Deborah K. Armstrong, Robert M. Wenham, William P. McGuire - Journal of Clinical Oncology 2007 cited by 756

  19. PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

    Authors: R. Wendel Naumann, Robert L. Coleman, Robert A. Burger, Edward A. Sausville, E. Kutarska, Sharad Ghamande, Nashat Gabrail, Stephen DePasquale, Elżbieta Nowara, Lucy Gilbert, Robert H. Gersh, Michael Teneriello, Wael A. Harb, Panagiotis A. Konstantinopoulos, Richard T. Penson, James T. Symanowski, C. Lovejoy, Christopher P. Leamon, David Morgenstern, Richard A. Messmann - Journal of Clinical Oncology 2013 cited by 233

  20. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience

    Authors: Kate Oliver, William E. Brady, Michael J. Birrer, David M. Gershenson, Gini F. Fleming, Larry J. Copeland, Krishnansu S. Tewari, Peter A. Argenta, Robert S. Mannel, Angeles Alvarez Secord, Jean-Marie Stephan, David G. Mutch, Frederick B. Stehman, Franco M. Muggia, Peter G. Rose, Deborah K. Armstrong, Michael A. Bookman, Robert A. Burger, John Farley - Gynecologic Oncology 2017 cited by 99

  21. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

    Authors: Angeles Alvarez Secord, Kirsten B. Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, John C. Brady, Heather A. Lankes, Herbert I. Hurwitz, Robert S. Mannel, Krishnansu S. Tewari, David M. O’Malley, Heidi J. Gray, Jamie N. Bakkum‐Gamez, Keiichi Fujiwara, Matthew Boente, Wei Deng, Robert A. Burger, Michael J. Birrer, Andrew B. Nixon - Clinical Cancer Research 2020 cited by 57

  22. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study

    Authors: Krishnansu S. Tewari, James Java, Ramez N. Eskander, Bradley J. Monk, Robert A. Burger - Annals of Oncology 2015 cited by 133

  23. BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer

    Authors: Ying L. Liu, Pier Selenica, Qin Zhou, Alexia Iasonos, Margaret K. Callahan, Noah Z. Feit, Julia L. Boland, Ignacio Vázquez-Garćıa, Diana Mandelker, Ahmet Zehir, Robert A. Burger, Daniel J. Powell, Claire F. Friedman, Karen A. Cadoo, Rachel N. Grisham, Jason Konner, Roisin E. O’Cearbhaill, Carol Aghajanian, Jorge S. Reis‐Filho, Britta Weigelt, Dmitriy Zamarin - JCO Precision Oncology 2020 cited by 50

  24. Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

    Authors: Gini F. Fleming, Virginia L. Brunetto, David Cella, Katherine Y. Look, Gary C. Reid, Adnan Munkarah, Richard Kline, Robert A. Burger, Annekathryn Goodman, R. Tucker Burks - Journal of Clinical Oncology 2004 cited by 567